Bill Sponsor
House Bill 1959
116th Congress(2019-2020)
Preserving Patient Access to Compounded Medications Act of 2019
Introduced
Introduced
Introduced in House on Mar 28, 2019
Overview
Text
Introduced
Mar 28, 2019
Latest Action
Mar 29, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1959
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Preserving Patient Access to Compounded Medications Act of 2019

This bill addresses regulations governing compounding pharmacies.

The bill expands the circumstances under which a drug may be compounded (i.e., manufactured at small scale) to allow pharmacists and physicians to compound drugs for administration to patients in an office or clinical setting, in accordance with state law. (Compounded drugs are not required to meet certain federal requirements regarding manufacturing, labeling, or approval.)

Dietary supplements may be used in the compounding of a drug.

The bill exempts from interstate distribution limits the dispensing of a compounded drug from the facility where it is compounded to a patient or health facility.

The bill limits the scope of Food and Drug Administration (FDA) inspections of compounding pharmacies to certain equipment, materials, containers, and labeling. This aligns the scope of inspections of compounding pharmacies with the scope of inspections of other pharmacies. (Currently, the scope of inspections of compounding pharmacies is the same as the scope of inspections of drug manufacturers.)

The bill also eliminates the requirement for compounding pharmacies to register with the FDA as drug manufacturers.
Text (1)
March 28, 2019
Actions (3)
03/29/2019
Referred to the Subcommittee on Health.
03/28/2019
Referred to the House Committee on Energy and Commerce.
03/28/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 6:47:27 PM